Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Core Viewpoint - Serina Therapeutics is advancing its proprietary POZ Platform drug delivery technology aimed at improving treatment for Parkinson's disease through continuous dopaminergic stimulation (CDS) [1][4]. Company Overview - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications [4]. - The company is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [4]. Upcoming Event - CEO Steven A. Ledger will present at Tribe Public's webinar titled "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on December 18, 2024 [1]. - The event will allow participants to submit questions to the CEO, enhancing engagement with stakeholders [3]. Technology and Product Development - Serina's POZ Platform aims to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs) [4].